Differences in Brain Derived Neurotrophic Factor Levels Between Chronic and Asymptomatic Pain Patients

Chronic Pain Clinical Trial

— BDNF  

Official title:

Differences in Brain Derived Neurotrophic Factor Levels Between Chronic and Asymptomatic Pain Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05736575
• Other study ID #: CCBDNF
• Status: Recruiting
• Start date: May 15, 2023
• Est. completion date: December 30, 2024

Study information

• Verified date: November 2023
• Source: Universidad Autonoma de Madrid
• Contact: Raúl Ferrer, PhD
• Phone: +34655412476
• Email: raul.ferrer[@]lasallecampus.es
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A case-control study will be conducted to analyze the differences in BDNF levels between patients with chronic pain and asymptomatic people.

Description:

Brain-derived neurotrophic factor (BDNF) is considered a biomarker of brain plasticity. Since different alterations in brain plasticity have been found in chronic pain patients, the investigators want to study whether there are differences at the molecular level in this population compared to an asymptomatic population in order to be able to accurately measure the impact of different physiotherapy interventions in an objective way.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 66
• Est. completion date: December 30, 2024
• Est. primary completion date: February 28, 2024
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• males and females aged 18 to 65 years with musculoskeletal pain for a minimum of 3 months

• patients recruited by information pamphlets from the university clinic of the Rey Juan Carlos University, and CSEU La Salle

• not having received physiotherapy treatment for this same process in the last 3 months.

• ability to perform all the clinical tests and to understand the study process, as well as to obtain informed consent.

Exclusion Criteria:

• Systemic, neurological, oncological or inflammatory diseases; psychiatric pathologies, pregnancy, type II diabetes.

Related Conditions & MeSH terms

• Chronic Pain

Intervention

Genetic:
• BDNF analysis (Elisa KIT)
Analysis of peripheral BDNF will be performed

Locations

Country	Name	City	State
Spain	Irf Cseuls	Madrid

Sponsors (2)

Lead Sponsor	Collaborator
Universidad Autonoma de Madrid	Universidad Rey Juan Carlos

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BDNF Levels	Brain Derived Neurotrophic Factor: Pierce NeutrAvidin-coated high-capacity plates (ThermoFisher Scientific; 15509) will incubate for two hours at RT with 200 µl of 14 µg/ml biotin-conjugated mAb-#1 diluted in phosphate buffer (0.1% Triton X-100 in 0.1 M phosphate buffer: 0.1 M KH2PO4 and 0.1 M Na2HPO4; pH 7.6). Plates will then washed three times with blocking buffer [1% bovine serum albumin (BSA); Sigma A2153 in phosphate buffer], followed by the addition of 150 µl phosphate buffer. A total of 50 µl of either standards or diluted samples (both in blocking buffer) will then added to the plate followed by incubation for 3 h at RT on a rotary shaker.	3 hours
Primary	Pain Intensity	Pain intensity assessed with the 100 mm Visual Analog Scale, in which the patient is asked about his or her pain level at that moment, with one side being "no pain" and the other extreme being "the worst pain imaginable"	3 hours